In the BioHarmony Drug Report Database

"Preview" Icon

Talazoparib

Talzenna (talazoparib) is a small molecule pharmaceutical. Talazoparib was first approved as Talzenna on 2018-10-16. It is used to treat breast neoplasms in the USA. It has been approved in Europe to treat breast neoplasms. The pharmaceutical is active against poly [ADP-ribose] polymerase 2 and poly [ADP-ribose] polymerase 1. Talzenna’s patents are valid until 2031-10-20 (FDA).

 

Trade Name

 

Talzenna
 

Common Name

 

talazoparib
 

ChEMBL ID

 

CHEMBL3137320
 

Indication

 

breast neoplasms
 

Drug Class

 

Poly-ADP-ribose polymerase inhibitors

Image (chem structure or protein)

Talazoparib structure rendering